SCHEMBL17307688

SCHEMBL17307688

CC1(C)c2ccccc2N(c2ccccn2)c2cc(Oc3cccc(N4c5ccccc5C(C)(C)c5cccnc54)c3)ccc21

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.39
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ LMNA P02545 2/20 0.33
▸ GRM5 P41594 2/20 0.32
▸ HTR1A P08908 1/20 0.31
▸ ADRA1D P25100 1/20 0.31
▸ ADRA1A P35348 1/20 0.31
▸ ADRA1B P35368 1/20 0.31
▸ KCNH2 Q12809 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ EGLN1 Q9GZT9 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17307690 0.89 GRM5 (0.35) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL17307687 0.84 ALDH1A1 (0.33) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL17307681 0.82 ALDH1A1 (0.37) ALDH1A1KMT2AMEN1GAAGRM5
SCHEMBL18590939 0.81 ALDH1A1 (0.33) ALDH1A1KMT2ALMNA
SCHEMBL13231487 0.81 LMNA (0.36) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL17291900 0.80 KDM4E (0.44) ALDH1A1KMT2AMEN1HTR1AADRA1D
SCHEMBL18289134 0.80 KMT2A (0.34) ALDH1A1KMT2AMEN1GAALMNA
SCHEMBL18289168 0.80 SMN1; SMN2 (0.30) SMN1; SMN2
SCHEMBL18289164 0.80 SMN1; SMN2 (0.30) SMN1; SMN2
SCHEMBL20168820 0.80 SMN1; SMN2 (0.42) ALDH1A1KMT2AGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-12-05 — — US disclosed
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2023-12-05 — — US disclosed
US-20210217973-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues UNIV ARIZONA STATE (US) 2021-07-15 — — US disclosed
US-11011712-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-05-18 — — US disclosed
US-20180226593-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2018-08-09 — — US disclosed
US-9941479-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-10 — — US disclosed
US-9941479-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-04-10 — — US disclosed
US-20150349279-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-12-03 — — US disclosed
US-20150349279-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY 2015-12-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180226593-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP ALDH1A1 1020/4885KMT2A 3281/4885MEN1 1196/4885
US-11011712-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues DPYD, DCTD, TYMP ALDH1A1 1020/4885KMT2A 3281/4885MEN1 1196/4885
US-20210217973-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP ALDH1A1 1020/4885KMT2A 3281/4885MEN1 1196/4885
US-20150349279-A1 Tetradentate Cyclometalated Platinum Complexes Containing 9,10-Dihydroacridine And Its Analogues DPYD, DCTD, TYMP ALDH1A1 1020/4885KMT2A 3281/4885MEN1 1196/4885
US-11839144-B2 Tetradentate cyclometalated platinum complexes containing 9,10-dihydroacridine and its analogues DPYD, DCTD, TYMP ALDH1A1 1020/4885KMT2A 3281/4885MEN1 1196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback